A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana

BMC Clinical Pathology

Joe-Nat Clegg-Lamptey¹  Benedict Calys-Tagoe³  Florence Dedey¹  Nii Armah Adu-Aryee¹  Bernard Seshie² 

[1] Department of Surgery, School of Medicine and Dentistry, University of Ghana, Accra, Ghana;Department of Surgery, Tema General Hospital, Tema, Ghana;Department of Community Health, School of Public Health, University of Ghana, Accra, Ghana

关键词: HER2;    PR;    ER;    Subtype;    Breast cancer;   

Others  :  1217869
DOI  :  10.1186/s12907-015-0014-4

 received in 2014-09-09, accepted in 2015-06-29,  发布年份 2015

【 摘 要 】

Background

Breast cancer is a heterogeneous disease composed of multiple subgroups with different molecular alterations, cellular composition, clinical behaviour, and response to treatment. This study evaluates the occurrence of the various subtypes and their clinical and pathological behaviour in the Ghanaian breast cancer population at the Korle Bu Teaching Hospital (KBTH).

Methods

Retrospective review of case notes of patients who had completed treatment for breast cancer at the KBTH within the last 5 years was conducted between April 2011 and March 2012. Subtypes were determined by immunohistochemistry classification based on expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2).

Result

A total of 165 cases contributed to this study. The mean age at diagnosis was 52.5 ± 12.1 years. Tumour size ranged from 0.8 cm to 15 cm with a mean of 4.9 ± 2.8 cm and median of 4 cm. Tumour grade was Grade I 8.3 %, Grade II 60.8 % and Grade III 30.8 %. ER, PR and HER2/neu receptor positivity was 32.1, 25.6 and 25.5 % respectively. Almost half (49.4 %) of the study population had triple negative tumours. Luminal A, luminal B and non-luminal HER2 were 25.6, 12.2, and 12.8 % respectively. No statistically significant association was seen between subtype and tumour size, tumour grade, lymph node status and age at diagnosis.

Conclusion

Triple negative tumour is the most occurring subtype in the Ghanaian breast cancer population treated at the Korle Bu Teaching Hospital. Lack of association seen between subtypes and their clinical and pathological behaviour could be due to small sample size.

【 授权许可】

   
2015 Seshie et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]WHO: The Global Burden of Disease: 2004 Update. 2008.
• [2]Jatoi I, Chen BE, Anderson WF, Rosenberg PS: Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis. J Clin Oncol 2007, 25(13):1683-1690.
• [3]Ries LA, Eisner MP, Kosary CL: Cancer Statistics review 1975-2000. National Cancer Institute 2003.
• [4]Newman LA: Breast Cancer in African American women. Oncologist 2005, 10:1-14.
• [5]Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester M, Kit Tse C, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Shelton Earp H, Millikan RC: Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
• [6]Baako BN, Badoe EA: Treatment of Breast Cancer in Accra: 5 year Survival. Ghana Med J 2001, 35:90-95.
• [7]Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, et al. (2010) Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Med 7(5): e1000279. doi:10.1371/journal.pmed.1000279
• [8]de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011, 137:183-192.
• [9]Rouzier R, Perou CM, Fraser Symmans W, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
• [10]Bergh J, Holmquist M: Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 2001, 30:103-108.
• [11]Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman M, Quayson SE, Zarbo R, Wicha M, Newman L: African Ancestry and Higher Prevalence of Triple-Negative Breast Cancer. Cancer 2010, 116:4926-4932.
• [12]Adebamowo AC, Famooto A, Ogundiran OT, Aniagwu T, Nkwodimmah C, Akang EE: Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008, 110:183-188.
• [13]Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957, 11(3):359-377.
• [14]Ohene-Yeboah M, Adjei E: Breast cancer in Kumasi, Ghana. Ghana Med J 2012, 46(1):8-13.
• [15]Perou CM, Sùrlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406.
• [16]Sørliea T, Perou CM, Tibshiranie R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Daleb AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(199):10869-10874.
• [17]Nielsen TO, Hsu FD, Jensen K, Cheng M, Karaca G, Hu Z, et al.: Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clin Cancer Res 2004, 10:5367-5374.
• [18]Huo D, Ikpatt F, Khramtsov A, Dangou J-M, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olapade IO: Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. J Clin Oncol 2009, 27:4515-4521.
• [19]Pang J, Toy KA, Griffith KA, Awuah B, Quayson S, Newman LA, Kleer CG: Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Breast Cancer Res Treat 2012, 135(1):59-66.
• [20]Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Da-browska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcı´a-Closas M: Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study. Cancer Epidemiol Biomarkers Prev 2007, 16:439-443.
• [21]Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20(9):2310-2318.
• [22]Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95(19):1482-1485.
• [23]Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G: Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat 2012, 134(1):353-362.
• [24]Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA: The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 2009, 9:86. BioMed Central Full Text
• [25]Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, Alvarez-Gómez RM, Herzog J, Castillo D, Royer R, Akbari M, Lara-Medina F, Herrera LA, Mohar A, Narod SA: The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat 2015, 150(2):389-394.
• [26]McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006, 66(16):8109-8115.
• [27]Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 2005, 365(9472):1687-1717.
• [28]Samphao S, Eremin JM, El-Sheemy M, Eremin O: Treatment of established breast cancer in post-menopausal women: role of aromatase inhibitors. Surgeon 2009, 7(1):42-55.
• [29]Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
• [30]Pienkowski T, Zielinski CC: Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol 2010, 21(5):917-924.
• [31]Carey LA, Claire DE, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM: The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res 2007, 13:2329-2334.
• [32]Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE: Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. J Clin Oncol 2010, 28(7):1145-1153.
• [33]Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O’Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008, 105(44):17079-17084.
• [34]Feigelson HS, James TA, Single RM, Onitilo AA, Aiello Bowles EJ, Barney T, Bakerman JE, McCahill LE: Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg 2013, 216(5):966-975.
• [35]Hanagiri T, Nagata Y, Monji S, Shinohara S, Takenaka M, Shigematsu Y, Shimokawa H, Nakagawa M, Uramoto H, So T, Tanaka F: Temporal trends in the surgical outcomes of patients with breast cancer. World J Surg Oncol 2012, 10:108. BioMed Central Full Text
• [36]McGuire KP, Santillan AA, Kaur P, Meade T, Parbhoo J, Mathias M, Shamehdi C, Davis M, Ramos D, Cox CE: Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 2009, 16(10):2682-2690.
• [37]Damle S, Teal CB, Lenert JJ, Marshall EC, Pan Q, McSwain AP: Mastectomy and contralateral prophylactic mastectomy rates: an institutional review. Ann Surg Oncol 2011, 18(5):1356-1363.
• [38]Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, del Turco MR, Ponti A: Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 2012, 48(13):1947-1956.
• [39]Dragun AE, Huang B, Tucker TC, Spanos WJ: Increasing mastectomy rates among all age groups for early stage breast cancer: a 10-year study of surgical choice. Breast J 2012, 18(4):318-325.
• [40]Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, Regine WF, Feigenberg SJ: Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol 2013, 20(5):1436-1443.
• [41]Garcia-Etienne CA, Tomatis M, Heil J, Danaei M, Rageth CJ, Marotti L, Rosselli Del Turco M, Ponti A: Fluctuating mastectomy rates across time and geography. Ann Surg Oncol 2013, 20(7):2114-2116.
• [42]Clegg-Lamptey J, Dakubo J, Attobra YN: Why do breast cancer patients report late or abscond during treatment in ghana? A pilot study. Ghana Med J 2009, 43(3):127-131.